Agree fully. The ASRE façade is finished, the gig is up, and the stock is already clinically dead. What’s left now is the inevitable slow decay familiar to anyone who has witnessed the afterlife of failed OTC tickers. These symbols rarely disappear immediately; instead, they rot in plain sight, drifting through years of meaningless existence, punctuated only by the occasional, unexplained flicker of volume, usually the mark of insiders or desperate bag-holders trying to create the illusion of life.
ASRE is no different. It will do what all hollowed-out shells do, hibernate in the .01–.02 purgatory, never fully delisted, never truly alive, just a corpse with a ticker symbol. These shells cling on because there is nothing left in them except the residue of failed promises and prior manipulation.
With the FBI looking seriously into ASRE, Loudoun and Claycamp, even that lingering half-life may soon be put out of its misery.
Bearish
Market Data 
Markets 
AI
